Fibroblasts in cancer

Nature Reviews Cancer

Volumn 6, Issue 5, 2006, Pages 392-401

  Kalluri, Raghu ^a,b   Zeisberg, Michael ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHEMOKINE; DESMIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROCOLLAGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 1; VIMENTIN; WNT1 PROTEIN;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL ACTIVATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; HOX GENE; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; PERICYTE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE PROGRESSION; FIBROBLASTS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33646384428     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1877     Document Type: Review

References (134)

1. Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nature Rev. Cancer 3, 422-433 (2003). A comprehensive review on ECM and tumour angiogenesis.
2. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971). The first publication to indicate that angiogenesis is a target for controlling cancer.
3. O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
4. Ishii, G. et al. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem. Biophys. Res. Commun. 309, 232-240 (2003).
5. Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
6. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
7. de Visser, K. E., Korets, L. V. & Coussens, L. M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423 (2005).
8. Tlsty, T. D. & Hein, P. W. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11, 54-59 (2001). An interesting review of tumour stromal cells and their role in oncogenic manipulation.
9. Elenbaas, B. & Weinberg, R. A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264, 169-184 (2001).
10. Mueller, M. M. & Fusenig, N. E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nature Rev. Cancer 4, 839-849 (2004). An in-depth review about tumour stroma.
11. Virchow, R. Die Cellularpathologie in Ihrer Begruendung auf Physiologische und Pathologische Gewebelehre (Hirschwald, A., Berlin, Germany, 1858).
12. Duvall, M. Atlas d'Embryologie (Masson, Paris, 1879).
13. Tarin, D. & Croft, C. B. Ultrastructural features of wound healing in mouse skin. J. Anat. 105, 189-190 (1969).
14. Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. & Brown, R. A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature Rev. Mol. Cell Biol. 3, 349-363 (2002).
15. Parsonage, G. et al. A stromal address code defined by fibroblasts. Trends Immunol. 26, 150-156 (2005).
16. Rodemann, H. P. & Muller, G. A. Characterization of human renal fibroblasts in health and disease: II. In vitro growth, differentiation, and collagen synthesis of fibroblasts from kidneys with interstitial fibrosis. Am. J. Kidney Dis. 17, 684-686 (1991).
17. Chang, H. Y. et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl Acad. Sci. USA 99, 12877-12882 (2002). This study compares primary fibroblasts that were isolated from various sites and sheds new light on the vast diversity of fibroblasts.
18. Simian, M. et al. The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development 128, 3117-3131 (2001).
19. Wiseman, B. S. & Werb, Z. Stromal effects on mammary gland development and breast cancer. Science 296, 1046-1049 (2002).
20. Castor, C. W., Wilson, S. M., Heiss, P. R. & Seidman, J. C. Activation of lung connective tissue cells in vitro. Am. Rev. Respir. Dis. 120, 101-106 (1979).
21. Muller, G. A. & Rodemann, H. P. Characterization of human renal fibroblasts in health and disease: I. Immunophenotyping of cultured tubular epithelial cells and fibroblasts derived from kidneys with histologically proven interstitial fibrosis. Am. J. Kidney Dis. 17, 680-683. (1991).
22. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000). A comprehensive review on cancer.
23. Ronnov-Jessen, L, Petersen, O. W. & Bissell, M. J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 76, 69-125 (1996).
24. Dvorak, H. F., Form, D. M., Manseau, E. J. & Smith, B. D. Pathogenesis of desmoplasia. I. Immunofluorescence identification and localization of some structural proteins of line 1 and line 10 guinea pig tumors and of healing wounds. J. Natl Cancer Inst 73, 1195-1205 (1984).
25. Dolberg, D. S., Hollingsworth, R., Hertle, M. & Bissell, M. J. Wounding and its role in RSV-mediated tumor formation. Science 230, 676-678 (1985).
26. Sieweke, M. H., Thompson, N. L., Sporn, M. B. & Bissell, M. J. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-β. Science 248, 1656-1660 (1990).
27. Brown, L. F. et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 5, 1041-1056 (1999).
28. Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94, 715-725 (1998).
29. Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985 (1983).
30. Dvorak, H. F. et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med. 174, 1275-1278 (1991).
31. Feng, D. et al. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J. Histochem. Cytochem. 48, 545-556 (2000).
32. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989).
33. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659 (1986).
34. Schedin, P. & Elias, A. Multistep tumorigenesis and the microenvironment. Breast Cancer Res. 6, 93-101 (2004).
35. Shekhar, M. P., Pauley, R. & Heppner, G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 5, 130-135 (2003).
36. van Kempen, L. C., Ruiter, D. J., van Muijen, G. N. & Coussens, L. M. The tumor microenvironment: a critical determinant of neoplastic evolution. Eur. J. Cell Biol. 82, 539-548 (2003).
37. Brown, L. F., Dvorak, A. M. & Dvorak, H. F. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am. Rev. Respir. Dis. 140, 1104-1107 (1989).
38. Folkman, J., Watson, K., Ingber, D. & Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61 (1989).
39. Chiquet-Ehrismann, R., Mackie, E. J., Pearson, C. A. & Sakakura, T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47, 131-139 (1986).
40. Mackie, E. J. et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc. Natl Acad. Sci. USA 84, 4621-4625 (1987).
41. Ishihara, A., Yoshida, T., Tamaki, H. & Sakakura, T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin. Cancer Res. 1, 1035-1041 (1995).
42. Brunner, A. et al. Prognostic significance of tenascin-C-expression in superficial and invasive bladder cancer. J. Clin. Pathol. 57, 927-931 (2004).
43. De Wever, O. & Mareel, M. Role of myofibroblasts at the invasion front. Biol. Chem. 383, 55-67 (2002).
44. Bertrand, P. et al. Hyaluronan (hyaluronic acid) and hyaluronectin in the extracellular matrix of human breast carcinomas: comparison between invasive and non-invasive areas. Int. J. Cancer 52, 1-6 (1992).
45. Barsky, S. H. & Gopalakrishna, R. Increased invasion and spontaneous metastasis of BL6 melanoma with inhibition of the desmoplastic response in C57 BL/6 mice. Cancer Res. 47, 1663-1667 (1987).
46. Netti, P A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J. & Jain, R. K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 60, 2497-2503 (2000).
47. Brown, E. B., Boucher, Y., Nasser, S. & Jain, R. K. Measurement of macromolecular diffusion coefficients in human tumors. Microvasc. Res. 67, 231-236 (2004).
48. Hynes, R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25 (1992).
49. Ryan, G. B. et al. Myofibroblasts in an avascular fibrous tissue. Lab. Invest. 29, 197-206 (1973).
50. Ryan, G. B. et al. Myofibroblasts in human granulation tissue. Hum. Pathol. 5, 55-67 (1974).
51. Tsukada, T., McNutt, M. A., Ross, R. & Gown, A. M. HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues. Am. J. Pathol. 127, 389-402 (1987).
52. Schor, S. L., Schor, A. M., Grey, A. M. & Rushton, G. Foetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells. J. Cell Sci. 90, 391-399 (1988).
53. Durning, P., Schor, S. L. & Sellwood, R. A. Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro. Lancet 2, 890-892 (1984).
54. Barsky, S. H., Green, W. R., Grotendorst, G. R. & Liotta, L. A. Desmoplastic breast carcinoma as a source of human myofibroblasts. Am. J. Pathol. 115, 329-333 (1984).
55. Sappino, A. P., Skalli, O., Jackson, B., Schurch, W. & Gabbiani, G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer 41, 707-712 (1988).
56. Gabbiani, G. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200, 500-503 (2003).
57. Ronnov-Jessen, L. & Petersen, O. W. Induction of α-smooth muscle actin by transforming growth factor-β1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. 68, 696-707 (1993).
58. Lohr, M. et al. Transforming growth factor-β1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res. 61, 550-555 (2001).
59. Aoyagi, Y. et al. Overexpression of TGF-β by infiltrated granulocytes correlates with the expression of collagen mRNA in pancreatic cancer. Br. J. Cancer 91, 1316-1326 (2004).
60. Akhurst, R. J. TGF-β antagonists: why suppress a tumor suppressor? J. Clin. Invest. 109, 1533-1536 (2002).
61. Bronzert, D. A. et al. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc. Natl Acad. Sci. USA 84, 5763-5767 (1987).
62. Forsberg, K., Valyi-Nagy, I., Heldin, C. H., Herlyn, M. & Westermark, B. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc. Natl Acad. Sci. USA 90, 393-397 (1993).
63. Shao, Z. M., Nguyen, M. & Barsky, S. H. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19, 4337-4345 (2000).
64. Armelin, H. A. Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc. Natl Acad. Sci. USA 70, 2702-2706 (1973).
65. Folkman, J. et al. A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am. J. Pathol. 130, 393-400 (1988).
66. Strutz, F. et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int. 57, 1521-1538. (2000).
67. Hay, E. D. An overview of epithelio-mesenchymal transformation. Acta Anat. 154, 8-20 (1995).
68. Thiery, J. P. Epithelial-mesenchymal transitions in tumor progression. Nature Rev. Cancer 2, 442-454 (2002). A good review on the role of EMT in cancer.
69. Kalluri, R. & Neilson, E. G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112, 1776-1784 (2003).
70. Fukino, K. et al. Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res. 64, 7231-7236 (2004).
71. Tuhkanen, H. et al. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int. J. Cancer 109, 247-252 (2004).
72. Ellsworth, D. L. et al. Genomic patterns of allelic imbalance in disease free tissue adjacent to primary breast carcinomas. Breast Cancer Res. Treat. 88, 131-139 (2004).
73. Kurose, K. et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nature Genet. 32, 355-357 (2002).
74. Petersen, O. W. et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am. J. Pathol. 162, 391-402 (2003). An interesting study indicating that cancer cells can contribute to the accumulation of stromal fibroblasts by undergoing a complete EMT.
75. Zeisberg, M. & Kalluri, R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J. Mol. Med. 82, 175-181 (2004).
76. Zeisberg, M. et al. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nature Med. 9, 964-968 (2003). The first study to indicate that targeting EMT can reduce the numbers of tissue fibroblasts and reverse fibrosis.
77. Iwano, M. et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341-350. (2002). Provides evidence that FSP1 protein is a fibroblast-specific protein, and provides further evidence relating to the role of EMT in organ fibrosis.
78. Kopelovich, L. Genetic predisposition to cancer in man: in vitro studies. Int. Rev. Cytol. 77, 63-88 (1982).
79. Schor, S. L. et al. Occurrence of a fetal fibroblast phenotype in familial breast cancer. Int. J. Cancer 37, 831-836 (1986).
80. Kuperwasser, C. et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 101, 4966-4971 (2004). Demonstrates that fibroblasts aid mammary epithelia in forming functional breast tissue, and carcinogenesis.
81. Bhowmick, N. A. et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851 (2004). Indicates that deletion of TCFβ type II receptor in FSP1-positive cells leads to the emergence of epithelial tumours.
82. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005). Indicates a prominent role for fibroblasts in tumour angiogenesis facilitated by SDF1.
83. Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011 (1999). A study that used co-culture methods to elucidate the role of CAFs in cancer progression.
84. Dimanche-Boitrel, M. T. et al. In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumor-associated myofibroblasts. Int. J. Cancer 56, 512-521 (1994).
85. Boire, A. et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313 (2005).
86. Stetler-Stevenson, W. G., Aznavoorian, S. & Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9, 541-573 (1993).
87. Sternlicht, M. D. et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137-146 (1999).
88. Lochter, A. et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 139, 1861-1872 (1997).
89. Olaso, E. et al. Tumor-dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. Hepatology 26, 634-642 (1997).
90. Olaso, E. et al. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 37, 674-685 (2003).
91. Cornil, I. et al. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc. Natl Acad. Sci. USA 88, 6028-6032 (1991).
92. mts1 gene. Cancer Res. 65, 3772-3780 (2005).
93. Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337 (2004).
94. Siegel, P. M. & Massague, J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nature Rev. Cancer 3, 807-821 (2003).
95. Bierie, B. & Moses, H. L. TGF-β and cancer. Cytokine Growth Factor Rev. 17, 29-40 (2006).
96. Derynck, R., Akhurst, R. J. & Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nature Genet. 29, 117-129 (2001).
97. Cheng, N. et al. Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF-mediated signaling networks. Oncogene 24, 5053-5068 (2005).
98. Silzle, T., Randolph, G. J., Kreutz, M. & Kunz-Schughart, L. A. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int. J. Cancer 108, 173-180 (2004).
99. Rettig, W. J. et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res. 53, 3327-3335 (1993).
100. Wang, X. M., Yu, D. M., McCaughan, G. W. & Gorrell, M. D. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology 42, 935-945 (2005).
101. Scott, A. M. et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. 9, 1639-1647 (2003).
102. Zeisberg, M. et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal Physiol. 285, F1060-F1067 (2003).
103. Zeisberg, M., Strutz, F. & Muller, G. A. Role of fibroblast activation in inducing interstitial fibrosis. J. Nephrol. 13 (Suppl.), S111-S120. (2000).
104. Nakamura, T et al. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am. J. Physiol. Heart Circ. Physiol. 288, H2131-H2139 (2005).
105. Kim, W. H., Matsumoto, K., Bessho, K. & Nakamura, T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am. J. Pathol. 166, 1017-1028 (2005).
106. Dai, C. et al. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. J. Am. Soc. Nephrol. 15, 2637-2647 (2004).
107. Isaka, Y. et al. Electroporation-mediated HGF gene transfection protected the kidney against graft injury. Gene Ther. 12, 815-820 (2005).
108. Yang, J., Dai, C. & Liu, Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J. Am. Soc. Nephrol. 13, 2464-2477 (2002).
109. McDonald, G. A. et al. Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am. J. Physiol. Renal Physiol. 285, F59-F67 (2003).
110. Heeg, M. H. et al. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 68, 96-109(2005).
111. Samuel, C. S. et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145, 4125-4133 (2004).
112. Seibold, J. R. et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 132, 871-879 (2000).
113. Binder, C. et al. Elevated concentrations of serum relaxin are associated with metastatic disease in breast cancer patients. Breast Cancer Res. Treat. 87, 157-166 (2004).
114. Binder, C., Hagemann, T., Husen, B., Schulz, M. & Einspanier, A. Relaxin enhances in-vitro invasiveness of breast cancer cell lines by up-regulation of matrix metalloproteases. Mol. Hum. Reprod. 8, 789-796 (2002).
115. Lazarides, E. & Balzer, D. R. Jr. Specificity of desmin to avian and mammalian muscle cells. Cell 14, 429-438 (1978).
116. Franke, W. W., Schmid, E., Osborn, M. & Weber, K. Different intermediate-sized filaments distinguished by immunofluorescence microscopy. Proc. Natl Acad. Sci. USA 75, 5034-5038 (1978).
117. Franke, W. W., Schmid, E., Osborn, M. & Weber, K. Intermediate-sized filaments of human endothelial cells. J. Cell Biol. 81, 570-580 (1979).
118. Mork, C., van Deurs, B. & Petersen, O. W. Regulation of vimentin expression in cultured human mammary epithelial cells. Differentiation 43, 146-156 (1990).
119. Schmid, E. et al. Distribution of vimentin and desmin filaments in smooth muscle tissue of mammalian and avian aorta. Exp. Cell Res. 137, 329-340 (1982).
120. Strutz, F. et al. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 130, 393-405 (1995).
121. Vogel, W., Gish, G. D., Alves, F. & Pawson, T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol. Cell 1, 13-23 (1997).
122. Goldsmith, E. C. et al. Organization of fibroblasts in the heart. Dev. Dyn. 230, 787-794 (2004).
123. Ramirez-Montagut, T. et al. FAPα, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene 23, 5435-5446 (2004).
124. 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Dev. Biol. 175, 301-313 (1996).
125. 1 integrin. J. Clin. Invest. 115, 2801-2810 (2005).
126. Mussini, E., Hutton, J. J. Jr & Udenfriend, S. Collagen proline hydroxylase in wound healing, granuloma formation, scurvy, and growth. Science 157, 927-929 (1967).
127. Langness, U. & Udenfriend, S. Collagen biosynthesis in nonfibroblastic cell lines. Proc. Natl Acad. Sci. USA 71, 50-51 (1974).
128. Florin, L. et al. Cre recombinase-mediated gene targeting of mesenchymal cells. Genesis 38, 139-144 (2004).
129. Hogan, B. L. & Yingling, J. M. Epithelial-mesenchymal interactions and branching morphogenesis of the lung. Curr. Opin. Genet. Dev. 8, 481-486 (1998).
130. Clayton, A. et al. Cellular activation through the ligation of intercellular adhesion molecule-1. J. Cell Sci. 111, 443-453 (1998).
131. Strieter, R. M. et al. Monocyte chemotactic protein gene expression by cytokine-treated human fibroblasts and endothelial cells. Biochem. Biophys. Res. Commun. 162, 694-700 (1989).
132. Rollins, B. J., Stier, P., Ernst, T. & Wong, G. G. The human homolog of the JE gene encodes a monocyte secretory protein. Mol. Cell. Biol. 9, 4687-4695 (1989).
133. Duda, D. G. et al. Differential transplantability of tumor-associated stromal cells. Cancer Res. 64, 5920-5924 (2004).
134. Grupp, C. et al. A novel model to study renal myofibroblast formation in vitro. Kidney Int. 59, 543-553 (2001).